Abstract
Amyloid β-peptide (Aβ), which plays a central role in Alzheimer Disease, is generated by presenilin-dependent and presenilin-independent γ-secretase cleavages of β-amyloid precursor protein (βAPP). We report that the presenilins (PS1 and PS2) also regulate p53-associated cell death Thus, we established that PS deficiency, catalytically inactive PS mutants, γ-secretase inhibitors and βAPP or APLP2 depletion reduced the expression and activity of p53, and lowered the transactivation of its promoter and mRNA levels. p53 expression was also reduced in the brains or βAPP-deficient mice or in brains where both PS had been invalidated by double conditional knock out. AICDC59 and AICDC50, the γ- and η- secretase-derived C-terminal fragments of βAPP, respectively, trigger the activation of caspase-3, p53-dependent cell death, and increase p53 activity and mRNA. Finally, HEK293 cells expressing PS1 harboring familial AD (FAD) mutations or FAD-affected brains, all display enhanced p53 activity and p53 expression. Our studies demonstrate that AICDs control p53 at a transcriptional level, in vitro and in vivo and unravel a still unknown function for presenilins.
Keywords: Presenilins, nicastrin, caspase-3, p53 expression, transcriptional activation
Current Alzheimer Research
Title: The γ /η-Secretase-Derived APP Intracellular Domain Fragments Regulate p53
Volume: 4 Issue: 4
Author(s): Frederic Checler, Claire Sunyach, Raphaelle Pardossi-Piquard, Jean Sevalle, Bruno Vincent, Toshitaka Kawarai, Nadege Girardot, Peter St George-Hyslop and Cristine Alves da Costa
Affiliation:
Keywords: Presenilins, nicastrin, caspase-3, p53 expression, transcriptional activation
Abstract: Amyloid β-peptide (Aβ), which plays a central role in Alzheimer Disease, is generated by presenilin-dependent and presenilin-independent γ-secretase cleavages of β-amyloid precursor protein (βAPP). We report that the presenilins (PS1 and PS2) also regulate p53-associated cell death Thus, we established that PS deficiency, catalytically inactive PS mutants, γ-secretase inhibitors and βAPP or APLP2 depletion reduced the expression and activity of p53, and lowered the transactivation of its promoter and mRNA levels. p53 expression was also reduced in the brains or βAPP-deficient mice or in brains where both PS had been invalidated by double conditional knock out. AICDC59 and AICDC50, the γ- and η- secretase-derived C-terminal fragments of βAPP, respectively, trigger the activation of caspase-3, p53-dependent cell death, and increase p53 activity and mRNA. Finally, HEK293 cells expressing PS1 harboring familial AD (FAD) mutations or FAD-affected brains, all display enhanced p53 activity and p53 expression. Our studies demonstrate that AICDs control p53 at a transcriptional level, in vitro and in vivo and unravel a still unknown function for presenilins.
Export Options
About this article
Cite this article as:
Checler Frederic, Sunyach Claire, Pardossi-Piquard Raphaelle, Sevalle Jean, Vincent Bruno, Kawarai Toshitaka, Girardot Nadege, George-Hyslop Peter St and da Costa Alves Cristine, The γ /η-Secretase-Derived APP Intracellular Domain Fragments Regulate p53, Current Alzheimer Research 2007; 4 (4) . https://dx.doi.org/10.2174/156720507781788945
DOI https://dx.doi.org/10.2174/156720507781788945 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adhesion Molecules and Kinases Involved in γ δ T Cells Migratory Pathways:Implications for Viral and Autoimmune Diseases
Current Medicinal Chemistry Searching Drug-Like Anti-cancer Compound(s) Based on G-Quadruplex Ligands
Current Pharmaceutical Design Antiplatelet Therapies: Platelet GPIIb / IIIa Antagonists and Beyond
Current Pharmaceutical Design 1'-methylspiro[indoline-3,4'-piperidine] Derivatives: Design, Synthesis, Molecular Docking and Anti-tumor Activity Studies
Letters in Drug Design & Discovery Editorial [Hot topic: MDMA (Ecstasy) Toxicity: Pharmacokinetic, Metabolism, Cell Response and Pathological Consequences (Guest Editor: Vittorio Fineschi)]
Current Pharmaceutical Biotechnology Aldo-Keto Reductase Family 1 Member B1 Inhibitors: Old Drugs with New Perspectives
Recent Patents on Anti-Cancer Drug Discovery Roles of Chemokine CXCL12 and its Receptors in Ischemic Stroke
Current Drug Targets Supercritical Fluid Particle Design of DPI Formulations (Review)
Current Pharmaceutical Design Therapeutic Use of Agonists of the Nuclear Receptor PPARγ in Alzheimers Disease
Current Alzheimer Research Retinoic Acid Induced 1, RAI1: A Dosage Sensitive Gene Related to Neurobehavioral Alterations Including Autistic Behavior
Current Genomics Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population
Current Alzheimer Research Vascular Cognitive Disorder: A Diagnostic and Pharmacological Treatment Updating
Current Psychopharmacology Feasibility of Assam Bora Rice Starch as a Compression Coat of 5-Fluorouracil Core Tablet for Colorectal Cancer
Current Drug Delivery Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Serotonin-Norepinephrine Reuptake Inhibitors for Pain Control: Premise and Promise
Current Neuropharmacology Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Role of Pharmacotherapy in Cardiac Ion Channelopathies
Current Vascular Pharmacology Pharmacology and Drug Discovery for T-Type Calcium Channels
CNS & Neurological Disorders - Drug Targets Artemisia Species as a New Candidate for Diabetes Therapy: A Comprehensive Review
Current Molecular Medicine The Role of Intravenous Dihydropyridine Calcium Channel Blockers in the Perioperative Management of Patients Undergoing Coronary Artery Bypass Surgery
Current Vascular Pharmacology